Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib

Clinical Nuclear Medicine

Volumn 34, Issue 6, 2009, Pages 346-349

  Chao, Heng Sheng ^a   Chang, Cheng Pei ^b,c   Chiu, Chao Hua ^b,c   Chu, Lee Shing ^b,c   Chen, Yuh Min ^b,c   Tsai, Chun Ming ^b,c  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Bone scintigraphy; Epidermal growth factor receptor tyrosine kinase inhibitor; Flare phenomenon; Gefitinib; Non small cell lung cancer

Indexed keywords

GEFITINIB; MEDRONATE TECHNETIUM TC 99M;

ADENOCARCINOMA; ADULT; ARTICLE; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; RADIOGRAPHY; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; ARTIFACTS; BIOPSY; BONE AND BONES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; RADIONUCLIDE IMAGING; RETROSPECTIVE STUDIES;

EID: 67650584196     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181a344df     Document Type: Article

References (29)

1. Alexander JL, Gilliespie PJ, Edelstyn GA. Serial bone scanning using technetium 99m diphosphonate in patients undergoing cyclical combined chemotherapy for advanced breast cancer. Clin Nucl Med. 1976;1: 13-17.
2. Janicek MJ, Hayes DF, Kaplan WD. Healing flare in skeletal metastases from breast cancer. Radiology. 1994;192:201-204.
3. Johns WD, Garnick MB, Kaplan WD. Leuprolide therapy for prostate cancer: an association with scintigraphic "flare" on bone scan. Clin Nucl Med. 1990;15:485-487.
4. Cook GJ, Fogelman I. The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med. 2001;31:206-211.
5. Coleman RE, Mashiter G, Whitaker KB, et al. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med. 1988;29:1354- 1359.
6. Schneider JA, Divgi CR, Scott AM, et al. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med. 1994;35:1748-1752.
7. Shepherd FA. Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin Oncol. 1999;26(suppl):3-11.
8. Lemieux J, Guimond J, Laberge F, et al. The bone scan flare phenomenon in non-small cell lung cancer. Clin Nucl Med. 2002;27:486-489.
9. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 15 2003;21: 2237-2246.
10. Chiu CH, Tsai CM, Chen YM, et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer. 2005;47:129-138.
11. Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res. 2005;11:3750-3757.
12. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149-2158.
13. Lin WC, Chiu CH, Liou JL, et al. Gefitinib as front-line treatment in Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2006;54: 193-199.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
15. Pollen JJ, Witztum KF, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Am J Roentgenol. 1984;142:773-776.
16. Stokkel MP, Valdes Olmos RA, Hoefnagel CA, et al. Tumor and therapy associated abnormal changes on bone scintigraphy: old and new phenomena. Clin Nucl Med. 1993;18:821-828.
17. Barista I. Biphosphonates and the flare phenomenon. J Clin Oncol. 1999;17: 1328-1329.
18. Cosolo W, Morstyn G, Arkles B, et al. Flare responses in small cell carcinoma of the lung. Clin Nucl Med. 1988;13:13-16.
19. White LM, Gray BG, Ichise M, et al. Scintigraphic flare in skeletal lymphoma. Clin Nucl Med. 1994;19:661-664.
20. Herrlin K, Willen H, Wiebe T. Flare phenomenon in osteosarcoma after complete remission. J Nucl Med. 1995;36:1429-1431.
21. Bitran JD, Bekerman C, Desser RK. The predictive value of serial bone scans in assessing response to chemotherapy in advanced breast cancer. Cancer. 1980;45:1562-1568.
22. Vogel CL, Schoenfelder J, Shemano I, et al. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol. 1995;13:1123-1128.
23. Koizumi M, Matsumoto S, Takahashi S, et al. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl Med. 1999;24:15-20.
24. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353:123-132.
25. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-1537.
26. Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) [abstract]. J Clin Oncol. 2006;24(suppl):7270.
27. Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer. 1997; 80(suppl):1595-1607.
28. Tarle M, Kovacic K, Strelkov-Alfirevic A. Correlation between bone scans and serum levels of osteocalcin, prostate-specific antigen, and prostatic acid phosphatase in monitoring patients with disseminated cancer of the prostate. Prostate. 1989;15:211-219.
29. Dehdashti F, Flanagan FL, Mortimer JE, et al. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51-56.